Chapter 1003 Hundred-billion-dollar market! Crazy academician!

"Why don't you just chat? Why are you so hesitant?" Bai Xi said suspiciously at this time.

She really didn't understand. Now that she was here, why didn't she take this opportunity to talk about business? Wouldn't it be more troublesome to make an appointment next time?

Tu Yanyan's mouth twitched.

You really don't regard the person in front of you as a big shot... Xu Qiu is the youngest academician in the country!

On weekdays, people who are qualified to cooperate with Xu Qiu have terrifyingly high status.

Whether you are free or can continue to chat, it's all up to Xu Qiu.

However, Xu Qiu didn't know Tu Yanyan's complicated psychological activities, and said directly: "Is it related to the development of new drugs?"

The only connection between him and Tu Yanyan was his cooperation with Jiade Medical.

"Yes..."

Tu Yanyan agreed, and added: "To be precise, our new drug development has encountered some obstacles."

"Obstacles?"

This is a bit strange. His new drug for multiple sclerosis once shined in the world competition and has also received a very high level of attention in China.

Anyone who is in this industry cannot fail to know who is behind Guardian Medical.

It would be fine if it didn't go all the way, so where did the obstacles come from?

Tu Yanyan smiled bitterly and said, "There was a problem with the approval process for the development and establishment of new drugs. It was rejected."

Hearing this, Xu Qiu narrowed his eyes slightly.

However, he didn't have too many emotions in his heart, and asked lightly, "What's the reason?"

If the new drug is not compliant, then it should be killed. If the project is not properly established, it is a pure waste of money in the field of drug development.

"Because... we infringed." Tu Yanyan's expression was bitter.

Xu Qiu was stunned.

Infringement?

What kind of rights were infringed?

He didn't quite understand that the new drug for multiple sclerosis was his project. Although it was applied for by Guardian Medical, the actual patent holder was still Xu Qiu himself... How could there be infringement?

I infringed on myself?

Tu Yanyan took out a stack of documents from her briefcase and handed it to Xu Qiu.

The latter took it, flipped through a few pages, and frowned tightly.

This stack of documents is the new drug research and development review materials submitted by Jiade Medical.

Roughly speaking, the research and development of new drugs has four stages.

The first is the approval before research and development, which is to say the project establishment.

After obtaining the license, preclinical trials begin. Through a series of laboratory and animal experiments, the best combination of compounds for treating diseases is found, and the compounds are proved to have biological activity against specific target diseases...

After that, clinical trials can be officially carried out.

The last step is to submit a complete version of the application materials, and this link is also the most difficult. The submitted documents alone may exceed 100,000 copies, including all the information of the drug, as well as analytical materials, data, etc.

Of course, the new multiple sclerosis drug is stuck in the first step, and even the project establishment has problems.

At the end of the review materials, there is a conspicuous "rejection" stamp.

Turning back, it is the specific explanation of not passing the review.

However, the more Xu Qiu read, the deeper his brows frowned.

Daxia attaches great importance to domestically developed drugs, so it offers considerable discounts.

These include speeding up approval, supporting the development of drugs for rare diseases and medical devices, etc., and the policy guarantees priority review and approval of various self-developed drugs.

However, the problem lies in the item of "supporting the development of drugs for rare diseases".

This item has a lot of content, one of which mentions "a certain degree of data protection period for the materials submitted by applicants for registration of innovative drugs, drugs for rare diseases, drugs for children, etc."

The starting point is good.

Once a new drug is developed, others will not be able to use the disclosed data to imitate low-priced substitutes.

However, the terrible thing is that before Jiade Medical, a team had already applied for the registration of a new drug for multiple sclerosis, and it was quickly approved.

As the original developer, Xu Qiu, on the contrary, was unable to establish a project due to the item "During the data protection period, any other applicant is prohibited from applying for the same product"!

"Doctor Xu, I have checked the information."

As he spoke, Tu Yanyan handed over another document.

The list of new drug approvals will not be open to the public in the early stage, and will only be entered in the clinical trial stage, but for people in the industry, it is not too difficult to obtain these materials.

Tu Yanyan handed over the project that collided with the new drug.

"Application date, February 7th..."

In addition, there are also materials such as the applicant and the applicant unit.

After reading it, Xu Qiu finally had a clear mind.

The other party took advantage of the time difference when he just came back from the world game and focused on the liver peace lawsuit, and directly applied for the development of new drugs first.

This practice is a bit similar to the preemptive registration in commercial behavior.

Xu Qiu originally thought that such a thing would not happen in the medical field. After all, medicine is a field with extremely deep barriers and strong professionalism. The bigwigs of various companies are closely connected and they see each other every day. It is impossible to be so shameless.

What's more, the applicant is actually another respected medical academician...

It is impossible to do such a thing that lowers one's own reputation.

However, this thing still happened... Xu Qiu was a little speechless, and could only sigh that the world is indeed a huge grass-roots team, and the real competition is so simple and crude.

In the eyes of ordinary people, academicians are already high-ranking bigwigs, as if they are carrying a high-end halo when eating, drinking, defecating and urinating, and their lives are only about the fierce confrontation of top academics and human knowledge.

However, when you really reach this level and sit on an equal footing with academicians, you will find that they are no different from ordinary people. They will still brag and plot.

It's just that the competition for a project worth tens of thousands or hundreds of thousands has become a competition for the leading qualification of an industry, or even the right to define a new market.

And new drugs for multiple sclerosis are obviously a market with unlimited prospects.

Tu Yanyan analyzed and said, "We estimate that this will be a market of over 100 billion US dollars... If the new drug for multiple sclerosis can be successfully developed, the sales in the first year will easily exceed 10 billion US dollars, and then it will gradually stabilize and hover between 20 and 30 billion... The 20-year patent protection period, even if countless unruly generic drugs will emerge during this period, is enough to create a market of 100 billion US dollars!"

Xu Qiu's coastal small blood vessels, with their relatively higher surgical threshold and technical difficulty, are destined to be unable to be fully rolled out in the field of cardiac surgery. Although the performance is superior, the profitability is really limited.

But the new drug for multiple sclerosis is different.

As long as the drug is developed, any patient can take it, and it will be useful after taking it!

Of course, what really made multiple sclerosis sit on the throne and made the academicians not hesitate to tear their faces with Xu Qiu was another point!